Professor Darren Ashcroft graduated in Pharmacy (BPharm) from the University of Nottingham and was awarded an MSc in Clinical Pharmacy (with Distinction) from the Queen’s University of Belfast and a PhD from the University of Aston. In 2002, he was appointed as Senior Clinical Lecturer at the University of Manchester. He was subsequently promoted to Reader in Medicines Usage and Safety in 2007 and Foundation Professor of Pharmacoepidemiology in 2010.
He is Director of the National Institute for Health Research (NIHR) Greater Manchester Patient Safety Translational Research Centre (GMPSTRC). He is an Honorary Professor at the Northern Care Alliance NHS Foundation Trust, and the University of Hong Kong. As the GMPSTRC’s Director, he leads the integration of an extensive programme of innovative research to improve patient safety across partner NHS Trusts, primary care networks, and the Universities of Manchester and Nottingham.
As well as his academic and clinical work, Darren is involved in a range of activities for the NIHR, National Institute of Health and Care Excellence (NICE), the Medicines and Healthcare Products Regulatory Agency (MHRA) and the UK National Health Service more widely. He sits on the Board of the NIHR School for Primary Care Research (SPCR) providing strategic leadership for research and capacity building to increase the evidence base for effective primary care practice.
For over 25 years, Darren has been a member of numerous local, regional, and national committees focused on medication usage and safety within the NHS. He regularly provides expert advice to the Department of Health and Social Care, including actions to improve medication safety following the third World Health Organization (WHO) Global Patient Safety Challenge “Medication Without Harm”, and to reduce overprescribing in the NHS. In 2017, he was appointed to the Pharmacovigilance Expert Advisory Group (PEAG) at the Medicines and Healthcare products Regulatory Agency (MHRA) and routinely provides expert advice on the public health importance of new safety signals and how these risks should be managed.
Memberships of committees and professional bodies
Darren has been a member of numerous local, regional and national committees focused on medication usage within the NHS. Current membership includes:
- Clinical Evaluation and Trials Prioritisation Group, National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme
- Patient Safety Advisory Committee, National Institute for Health and Clinical Excellence (NICE)
- Prescribing Indicators National Group (PING), Department of Health
- Technology Appraisals Committee, National Institute for Health and Clinical Excellence (NICE)
Memberships of Professional Organisations
- Academic Pharmacy Group
- International Society of Pharmacoepidemiology (ISPE)
- Royal Pharmaceutical Society of Great Britain
- UK Drug Utilisation Review Group (DURG)